The mental health treatment recommendation provider secured the money in a round backed by Providence Health & Services and strategic partner Castlight Health.

The genetics testing company has managed to attract a range of corporate investors, partly through its research activities, and international expansion looks to be on the horizon.

GlaxoSmithKline took part in the round and secured a board seat at the startup, which is developing treatments for hearing disorders.

The genetic testing company has now raised $225m after Alphabet, Illumina and WuXi PharmaTech took part in a Fidelity-led round that valued it at $1.1bn.

Harvard life sciences spinout Ultivue secures $5.15m in series A backed by Arch Venture Partners.

Minoryx has raised $22.1m from backers including Roche and Chiesi, and will look to advance its lead Orphan disease therapy through clinical testing.

Galera Therapeutics, which develops therapies to prevent side effects from cancer treatments, has completed a Novo-led series B round also featuring Novartis.

The pharmaceutical firm is following a $35m investment in Gamida Cell last year with up to $15m of cash over the next two years.

Voyager Therapeutics, which is developing treatments for central nervous system diseases, has raised $124m from investors including Aventis.